{"id":"d4174aa7-a691-5a60-afe9-1961eee24b72","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:statin-therapy-and-incident-diabetes","predicate":"increases","statement":"Statin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"34abdffb-8374-55e6-be48-0611b9a95c68","mechanism_event_label":"Statin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.","subject":{"id":"4c58906d-dbdd-5b59-9849-3f26f120062e","slug":"statin-therapy","display_name":"Statin therapy as a drug class","entity_type_key":"chemical_species"},"object":{"id":"90852736-7ac8-51f6-8400-14b305f28ab1","slug":"incident-diabetes-risk","display_name":"Incident diabetes mellitus","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"34abdffb-8374-55e6-be48-0611b9a95c68","stable_key":"1fb6218a-60d1-55ea-87fe-07d15d0fc46f:statin-therapy-and-incident-diabetes-event","event_type":"observed_relationship","label":"Statin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.","description":"Statin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4c58906d-dbdd-5b59-9849-3f26f120062e","slug":"statin-therapy","display_name":"Statin therapy as a drug class","entity_type_key":"chemical_species"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"90852736-7ac8-51f6-8400-14b305f28ab1","slug":"incident-diabetes-risk","display_name":"Incident diabetes mellitus","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"duration","value_text":"Mean 4 years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Meta-analysis of 13 statin trials with 91,140 participants, of whom 4,278 developed diabetes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Statin therapy in trials of more than 1,000 patients lasting more than one year","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A class-level association across statins and doses, not an atorvastatin-specific or mechanism-specific result, and derived from trials whose primary endpoints were cardiovascular.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"organism","value_text":"Meta-analysis of 13 statin trials with 91,140 participants, of whom 4,278 developed diabetes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Statin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. (2010). https://pubmed.ncbi.nlm.nih.gov/20167359/ DOI: 10.1016/S0140-6736(09)61965-6","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"New-onset diabetes mellitus","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"a2a0fd76-4a6c-57f7-908b-a5354a235c3a","evidence_kind":"source_excerpt","locator":"Lines 188-197","start_line":188,"end_line":197,"excerpt":"## statin-therapy-and-incident-diabetes\nStatin therapy was associated with a 9 percent increased risk of incident diabetes across 13 randomised trials.\nModel/species: Meta-analysis of 13 statin trials with 91,140 participants, of whom 4,278 developed diabetes\nTissue/system: New-onset diabetes mellitus\nExposure: Statin therapy in trials of more than 1,000 patients lasting more than one year\nRoute: Oral\nDuration: Mean 4 years\nLimits: A class-level association across statins and doses, not an atorvastatin-specific or mechanism-specific result, and derived from trials whose primary endpoints were cardiovascular.\nPrimary reference: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. (2010). https://pubmed.ncbi.nlm.nih.gov/20167359/ DOI: 10.1016/S0140-6736(09)61965-6\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"","directness":"reported_statement","verification_status":"source_derived_draft","notes":"","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a4431d8c-34d7-5db7-9edf-a35f68feba39","stable_key":"import-1fb6218a-60d1-55ea-87fe-07d15d0fc46f","title":"Atorvastatin: mechanism of action from target occupancy to isoprenoids, transport, muscle and metabolism (2026-09-22)","document_type":"imported_text","citation_label":"Original AI-assisted curation of twelve primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Findings obtained with mevastatin, simvastatin or the statin class are recorded against those subjects. Study-specific citations, doses, negative findings and limitations retained. Not publisher full text.","file_path":"","sha256":"6307f1acf99f90662320328974781ee660348754257b1e1555701ad597edc8e5","revision_id":"447c5978-ba3f-58fe-ac85-664caa72e01b","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}